Table 4.
The clinical trials of mRNA cancer vaccine based on direct injection.
| Company or Institution |
Delivery Vehicle | Tumor Types | Antigens | Phase | Status | NCT Number |
|---|---|---|---|---|---|---|
| CureVac AG | Protamine | Non-small-cell lung cancer | MUC1, survivin, NY-ESO-1, 5T4, MAGE-C2, MAGE-C1 | Phase I/II | Completed | NCT03164772 |
| University Hospital Tuebingen | Not mentioned | Malignant melanoma | Melan-A, Mage-A1, Mage-A3, Survivin, GP100, tyrosinase | Phase I/II | Completed | NCT00204516 |
| University Hospital Tuebingen | Protamine | Malignant melanoma | Melan-A, Mage-A1, Mage-A3, Survivin, GP100, and tyrosinase | Phase I/II | Completed | NCT00204607 |
| Merck | Not mentioned | Non-small-cell lung cancer, pancreatic neoplasms, colorectal neoplasms |
mRNA-5671/V941 | Phase I | Recruiting | NCT03948763 |
| BioNTech | Lipid-based vector | Ovarian cancer | Ova | Phase I | Recruiting | NCT04163094 |
| Moderna | Lipid-based vector | Melanoma | Personalized mRNA-4157 | Phase II | Recruiting | NCT03897881 |
| Moderna | Lipid-based vector | Solid tumors | Personalized mRNA-4157 | Phase I | Recruiting | NCT03313778 |
| BioNTech | Lipid-based vector | Prostate cancer | W_pro1 | Phase I/II | Recruiting | NCT04382898 |
| Universitair Ziekenhuis Brussel | Naked mRNA | Early-stage breast cancer | - | Phase I | Recruiting | NCT03788083 |
| National Cancer Institute | Lipid-based vector | Melanoma, colon cancer, gastrointestinal cancer, genitourinary cancer, hepatocellular cancer | Personalized mRNA | Phase I/II | Terminated | NCT03480152 |
| University Hospital Tuebingen | Protamine | Recurrent prostate cancer | - | Phase I/II | Unknown | NCT02452307 |
| University of Florida | Lipid-based vector | Adult glioblastoma | Autologous total tumor and pp65 full-length (fl) lysosome-associated membrane protein (LAMP) | Phase I | Recruiting | NCT04573140 |
| Moderna | Lipid-based vector | Relapsed/refractory solid tumor malignancies or lymphoma | human OX40L | Phase I/II | Active, not recruiting | NCT03323398 |
| BioNTech | Lipid-based vector | Melanoma | NY-ESO-1, tyrosinase, MAGE-A3, TPTE |
Phase I | Active, not recruiting | NCT02410733 |
| BioNTech SE | Lipid-based vector | Breast cancer | Tumor relevant and immunogenic RNA |
Phase I | Active, not recruiting | NCT02316457 |
| CureVac AG | Peptide-based vector | Non-small-cell lung cancer | CV9201 | Phase I/II | Completed | NCT00923312 |
| CureVac AG | Peptide-based vector | Non-small-cell lung cancer | CV9202 | Phase I | Terminated | NCT01915524 |
| CureVac AG | Peptide-based vector | Prostate cancer | CV9103 | Phase I/II | Completed | NCT00831467 |
| CureVac AG | Peptide-based vector | Prostate cancer | CV9103 | Phase I/II | Terminated | NCT00906243 |
| CureVac AG | Peptide-based vector | Prostate cancer | CV9104 | Phase I/II | Terminated | NCT01817738 |
| CureVac AG | Peptide-based vector | Prostate cancer | CV9104 | Phase II | Terminated | NCT02140138 |
| Moderna | Lipid-based vector | Solid tumor malignancies or lymphoma | mRNA-2752 | Phase I | Recruiting | NCT03739931 |
| Stemirna Therapeutics | Not mentioned | Esophageal cancer, non-small-cell lung cancer | Personalized mRNA | Not applicable | Not yet recruiting | NCT03908671 |
| Changhai Hospital | Not mentioned | Advanced Esophageal Squamous; Carcinoma; Gastric Adenocarcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma | Personalized mRNA | Not applicable | Recruiting | NCT03468244 |
| Laura Esserman | Not mentioned | Carcinoma, intraductal, noninfiltrating |
mRNA 2752 | Phase I | Recruiting | NCT02872025 |
| University Medical Center Groningen | Not mentioned | Cervical cancer | HPV-derived tumor antigens |
Phase I | Completed | NCT03141463 |